Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

by divibasicbldev | Jul 20, 2023 | Press Releases

Proposal Does Not Adequately Reflect Pasithea’s Strategic Value and Prospects for Continued GrowthPALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

by divibasicbldev | Jun 30, 2023 | Press Releases

Special Committee Continues to Actively Evaluate Unsolicited Proposal from Lucy Scientific Discovery Inc.PALO ALTO, Calif. and MIAMI, June 30, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...

Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004

by divibasicbldev | Jun 29, 2023 | Press Releases

— Represents the final step before submission of Investigational New Drug (IND) application to FDA, expected in the second half of 2023 –PALO ALTO, Calif. and MIAMI, June 29, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA)...

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

by divibasicbldev | Jun 6, 2023 | Press Releases

PALO ALTO, Calif. and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments...

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

by divibasicbldev | Jun 1, 2023 | Press Releases

Features Preclinical data of PAS-004 in Plexiform NeurofibromaPALO ALTO, Calif. and MIAMI, June 01, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the...